Loading...
•
Mar 31, 2023
Sight Sciences Q1 2023 Earnings Report
Reported financial results for the first quarter ended March 31, 2023 and reaffirmed guidance for full year 2023.
Key Takeaways
Sight Sciences reported a 26% increase in revenue for the first quarter of 2023, driven by the adoption of surgical glaucoma and dry eye technologies. The company reaffirmed its full-year revenue guidance and expects improved operating leverage.
Generated first quarter revenue of $18.8 million, an increase of 26% compared to the prior year period
Achieved gross margin of 84% in the first quarter of 2023 versus 80% in the first quarter of 2022
Completed the commercial launch of the Ergo-Series OMNI® Surgical System
Net loss was $17.1 million ($0.35 per share) in the first quarter of 2023, as compared to $23.3 million ($0.49 per share) in the prior year period.
Revenue by Segment
Forward Guidance
Sight Sciences reaffirms revenue guidance expectations for the full year 2023 of $89.0 million to $94.0 million, which represents growth of approximately 25% to 32% compared to 2022. The Company also reaffirms its expectation for average adjusted operating expense on a quarterly basis of approximately $30.5 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...